Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of UA007 for prevention of chemotherapy-induced diarrhea in colorectal cancer patients receiving FOLFIRI
CTR20221604Phase 2Active
- Sponsor
- Jiaochen Biopharmaceutical
- Start
- Sep 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of UA007 in diarrhea, sponsored by Jiaochen Biopharmaceutical. Started Sep 2022; status: active.
02
Drugs
UA007
03
Conditions
diarrhea
Beyond the preview
Go deeper on CTR20221604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221604.